Roche Reports the P-IIb (PADOVA) Trial Data of Prasinezumab for Early-Stage Parkinson’s Disease
Shots:
- The P-IIb (PADOVA) study assessed safety & efficacy of prasinezumab (1500mg, IV, Q4W) vs PBO in subjects (n=586) with early-stage Parkinson’s disease, on stable symptomatic treatment, for at least 76wks.
- Study depicted effectiveness in the 1EP of time to confirmed motor progression but was insignificant, a strong efficacy in pre-specified analysis among 75% levodopa-treated subjects & positive trends across exploratory & 2EPs. Safety profile was well-tolerated without any new concerns. Full data will be highlighted at future conferences
- In addition, the P-II (PASADENA) & P-IIb (PADOVA) extension trials are underway to explore effects, with Roche collaborating with health authorities on next steps
Ref: Roche | Image: Roche
Related News:- Roche Reports the EMA’s Approval of Vabysmo Prefilled Syringe (PFS) for three Retinal Conditions Causing Blindness
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
